Oncolytic activity of the rhabdovirus VSV-GP against prostate cancer

Area of Science:

• Virology
• Oncology
• Gene Therapy

Background:

• Prostate cancer, particularly metastatic disease, lacks curative treatment options.
• Oncolytic viruses offer a novel therapeutic approach by selectively targeting and destroying cancer cells.

Purpose of the Study:

• To evaluate the efficacy of vesicular stomatitis virus-GP (VSV-GP) against prostate cancer.
• To investigate VSV-GP's effectiveness in preclinical prostate cancer models, including metastatic disease.

Main Methods:

• VSV-GP infectivity was tested against multiple prostate cancer cell lines.
• Interferon (IFN) alpha treatment effects on VSV-GP susceptibility were assessed.
• Prostate cancer mouse models were used to evaluate VSV-GP efficacy via intratumoral and intravenous administration.

Main Results:

• VSV-GP demonstrated high infectivity in most prostate cancer cell lines.
• Reduced susceptibility was observed in cell lines with low receptor expression or following IFN-alpha treatment.
• Long-term remission was achieved in mouse models with both subcutaneous tumors and bone metastases after VSV-GP treatment.

Conclusions:

• VSV-GP is a potent oncolytic virus against prostate cancer in preclinical settings.
• The findings support the further development of VSV-GP for systemic treatment of metastatic prostate cancer.